NASDAQ
Gene Biotherapeutics, Inc. (CRXM) has a free cash flow growth of 30.08% as of Friday, May 29, 2026. This represents a 124.40% increase compared to its 12-month average of -123.26%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.